Myeloid-specific NG2 ablation in these mice, previously reported in the case of brain tumors [28], is confirmed here (Fig. 1) by comparisons of sham-operated and lysolecithin-injected spinal cords from control, OPC-NG2ko, and My-NG2ko mice via immunolabeling for NG2 and the myeloid markers CD18, CD11b, and F4/80, respectively. The gene discussed is CSPG4; the disease is brain neoplasm.